Five standards carry the weight: a named, state-licensed dispensing pharmacy, a prescriber licensed where the patient is, semaglutide base rather than a salt form, refrigerated shipping that arrives cold, and a label showing the real pharmacy name with usable directions. FDA has published concerns about failures in every one of them.
The checkout page is not the pharmacy
An online semaglutide program is usually an interface stitched over at least two other regulated businesses: a medical practice that employs prescribers, and a pharmacy that prepares and ships. The brand on the box, the brand on the website, and the brand on the shipping label are frequently three different companies. FDA’s guidance to patients is direct on this point: obtain a prescription from a clinician and fill it at a state-licensed pharmacy. Neither half of that instruction can be confirmed if the pharmacy is never identified.
Where the preparation is made changes what exists to look up
Traditional compounding pharmacies operate under state boards and prepare medication for identified patients. Outsourcing facilities register with FDA and can produce batches, which places them under federal inspection and reporting expectations. Registration is a status, not an endorsement of any product, and the practical difference for a patient is the paper trail available afterward. FDA has warned outsourcing facilities over repackaging of unapproved GLP-1 material, and has warned active ingredient distributors over selling such material to compounders, so the category alone does not settle quality.
Source material is also being policed at the border. FDA established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, with a list of manufacturers that appear to meet manufacturing standards excluded from it. That mechanism exists because ingredient origin, not just pharmacy category, determines what ends up in a vial.
Salt forms are a different active ingredient
This is the most specific thing FDA has said about compounded semaglutide, and the easiest for a patient to ask about. Semaglutide sodium and semaglutide acetate are not the active ingredient used in approved products. The agency has said it lacks information on whether those salts have the same chemical and pharmacologic properties, and that it is not aware of a lawful basis for their use in compounding. A pharmacy should be able to state in one sentence that it dispenses semaglutide base.
Cold chain, and what a failed one looks like
Approved semaglutide injections are refrigerated products. The labeling directs storage between 36 and 46 degrees Fahrenheit, allows a limited period at room temperature that is measured in days rather than weeks, prohibits freezing, and instructs that the product stay in its original carton to protect it from light. FDA has received complaints of compounded GLP-1 shipments arriving warm or with ice packs inadequate for the trip, and recommends that an injectable GLP-1 arriving warm not be used.
Replacement policy for a warm delivery is rarely printed next to the price, so it needs asking before the first order. Where a program does publish operational detail, shipping terms tend to sit alongside the monthly figure rather than in an FAQ, and reading the pricing page next to the shipping page shows how much of the risk sits with the patient and how much sits with the provider behind it. Manufacturer channels such as NovoCare Pharmacy ship the approved products under the storage conditions on their own labeling, which is a different arrangement from a compounded vial packed for a two-day courier.
Reading the box when it lands
FDA has documented fraudulent compounded semaglutide and tirzepatide carrying false label information, including labels naming pharmacies that do not exist and labels naming real pharmacies that did not make the product. Its consumer warning signs include spelling errors on the label and incorrect pharmacy addresses. A patient can check a printed pharmacy name against the state board register in about two minutes, which is the cheapest verification step available anywhere in this process.
Dose measurement belongs in the same inspection. FDA has received reports of adverse events, some involving hospitalization, tied to dosing errors with compounded injectable semaglutide, including patients measuring incorrect volumes and clinicians miscalculating doses. A poison center case series described the same pattern. Multi-dose vials with syringes shift arithmetic onto the patient in a way a single-dose pen does not, and the directions that arrive with the vial are the control for that.
| Shipment element | What a compliant delivery shows | What a problem looks like |
|---|---|---|
| Pharmacy identity | Full name, address, and state that match a board register | No pharmacy named, or an address that does not resolve |
| Prescriber record | Signing clinician named on the label or paperwork | Only a platform name appears anywhere |
| Active ingredient | Semaglutide base stated on the label or the paperwork | A salt form, or an ingredient line left vague |
| Temperature | Cold on arrival, with intact coolant for the transit time | Warm box, melted packs, or no coolant at all |
| Directions | Strength, volume per dose, and administration steps | Strength without volume, or no instructions in the box |
| Beyond-use date | A date printed and consistent with the refill interval | Missing date, or one that expires mid-cycle |
Confirming the clinician who signed
Every state publishes a searchable license register for physicians, nurse practitioners, and physician assistants, showing status, issue date, and disciplinary history. The name to search is the one on the prescription, not the medical director listed on an about page. Where the two are never the same person and the signing name changes every refill, ask who holds continuity of the chart, because dose adjustment for gastrointestinal intolerance depends on someone knowing what happened at the previous step.
The gap between providers is often just a matter of what they will put in writing before payment. HealthRX sits alongside options like Eden and Found in publishing pharmacy relationships and prescriber credentials on its semaglutide page, so the register checks described here can be done in advance. A service that saves those names for the shipping label leaves the verification until it is nearly moot.
Frequently asked questions
Does track and trace under federal supply chain law cover compounded semaglutide?
The Drug Supply Chain Security Act builds product tracing around approved prescription drugs moving through the distribution system. Compounded preparations are made by a pharmacy for dispensing rather than distributed as approved products, so the serialized trail that exists for a brand pen does not exist in the same form here.
What should happen if a vial arrives warm?
FDA advises against using an injectable GLP-1 that arrives warm or with insufficient refrigeration, because temperature excursions can affect quality. The practical follow-up is a documented replacement at no charge. Photograph the packaging and the coolant on opening, since that record is what a replacement request rests on.
Is a registered outsourcing facility a safer source than a compounding pharmacy?
Not by category alone. Registration brings federal inspection and reporting into the picture, which is meaningful, but FDA has issued warnings involving outsourcing facilities as well. What separates sources in practice is ingredient origin, documented preparation, and whether the facility will answer questions in writing.
How does a patient verify the ingredient is not a salt form?
Ask the pharmacy directly, in writing, whether the preparation uses semaglutide base. A pharmacy that prepares the medication knows the answer without research. Reluctance to put it in writing is informative, given that the agency has named the salt forms as different active ingredients from the approved one.
Sources
- FDA, Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. https://www.fda.gov/drugs/drug-alerts-and-statements/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
- FDA, How to Buy Medicines Safely From an Online Pharmacy. https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy
- FDA, Counterfeit Medicine. https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
- FDA, Drug Supply Chain Security Act. https://www.fda.gov/drugs/drug-supply-chain-integrity/drug-supply-chain-security-act-dscsa
- FDA, Human Drug Compounding Laws and Policies. https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies
- DailyMed, OZEMPIC (semaglutide) injection prescribing information. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=adec4fd2-6858-4c99-91d4-531f5f2a2d79
- Administration errors of compounded semaglutide reported to a poison control center. https://pubmed.ncbi.nlm.nih.gov/37392810/
- Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study. https://pubmed.ncbi.nlm.nih.gov/40285721/
By
By
